Related Experiment Video

Updated: Jun 22, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Coronary artery disease: Platelet activity: an obstacle for successful PCI

Meinrad Gawaz, Tobias Geisler

    Nature Reviews. Cardiology
    |May 28, 2009
    PubMed

    Insights

    Dual antiplatelet therapy with aspirin and clopidogrel helps prevent coronary events after stenting. However, variable patient responses to clopidogrel may indicate a risk for stent thrombosis.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Thrombosis Research

    Background:

    • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for patients undergoing coronary stenting.
    • While effective, variability in platelet response to clopidogrel poses a risk.
    • Stent thrombosis remains a serious complication in up to 3% of patients.

    Discussion:

    • Investigating clopidogrel responsiveness is crucial for risk stratification.
    • Understanding individual patient responses can guide therapeutic adjustments.
    • This research explores the link between platelet reactivity and adverse thromboischemic events.

    Key Insights:

    • Patient platelet reactivity to clopidogrel varies significantly.
    • This variability is associated with an increased risk of post-stenting thromboischemic events.
    • Assessing clopidogrel responsiveness may identify high-risk individuals.

    Outlook:

    • Further research is needed to validate clopidogrel responsiveness as a predictive marker.
    • Personalized antiplatelet strategies could improve outcomes after coronary stenting.
    • Developing more effective antiplatelet therapies remains a priority.

    More Related Videos

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    Related Concept Videos

    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Peripheral Artery Disease I: Introduction01:30

    Peripheral Artery Disease I: Introduction

    Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Coronary Artery Disease II: Pathophysiology01:26

    Coronary Artery Disease II: Pathophysiology

    Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
    Formation of the Platelet Plug01:22

    Formation of the Platelet Plug

    The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
    As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...